期刊文献+

液相色谱-串联质谱法测定人血浆中匹伐他汀 被引量:9

Determination of pitavastatin in human plasma by liquid chromatographytandem mass spectrometry
下载PDF
导出
摘要 目的:建立灵敏、快速的液相色谱-串联质谱(LC-MS-MS)法测定人血浆中匹伐他汀,并用于药动学研究。方法:血浆样品经乙腈沉淀蛋白后,以乙腈-5 mmol·L^(-1)醋酸铵溶液(90:10,V:V)为流动相,Zorbax XDB C_8柱分离。采用电喷雾电离源(ESI),以多反应监测(MRM)方式进行正离子检测。用于定量分析的离子分别为m/z 422→m/z 290(匹伐他汀)和m/z 515→m/z 276(内标,替米沙坦)。结果:测定血浆中匹伐他汀的线性范围为0.1~100μg·L^(-1),定量下限为0.1μg·L^(-1)。日内、日间精密度(RSD)均小于12.0%,准确度(RE)在±2.4%以内。结论:该方法选择性好、灵敏度高、操作简便,适用于匹伐他汀的临床药动学研究。 AIM: To develop a LC-MS-MS and study the pharmacokinetics of pitavastatin. method for the determination of pitavastatin in human plasma METHODS: Pitavastatin and telmisartan (internal standard) were isolated from plasma using protein precipitation with acetonitrile, and then separated on a Zorbax XDB C8 column. The mobile phase consisted of acetonitrile-5 mmol·L^-1 ammonium acetate (90 : 10, V : V), at a flowrate of 0.6 mL·min^-1. An API 4000 tandem mass spectrometer equipped with electrospray ionization was used as detector and was operated in the positive ion mode. Multiple reaction monitoring (MRM) using the precursor to product ion combinations of m/z 422 → m/z 290 and m/z 515 → m/z 276 was performed to quantify pitavastatin and the internal standard, respectively. RESULTS: The calibration curves were linear over the range of 0.1-100 μg·L^-1. The lower limit of quantification was 0.1 μg·L^-1. The intra-day and inter-day relative standard deviation (RSD) across three validation runs over the entire concentration range was less than 12.0 %. The accuracy was within ± 2.4 %. CONCLUSION: The method is sensitive, selective and proved to be suitable for clinical investigation of pitavastatin pharmacokinetics.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第11期805-808,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 匹伐他汀 色谱法 高压液相 光谱法 质谱 电喷雾电离 药动学 pitavastatin chromatography, high pressure liquid spectrometry, mass, electrospray ionization pharmacokinetics
  • 引文网络
  • 相关文献

参考文献6

  • 1MUKHTAR RY, REID J, RECKLESS JP. Pitavastatin[J]. Int J Clin Pract, 2005, 59(2): 239-252.
  • 2HUI CK, CHEUNG BM, LAU GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis[J]. Br J Clin Pharmacol, 2005, 59(3): 291-297.
  • 3KAJINAMI K, TAKEKOSHI N, SAITO Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reduetase inhibitor[J]. Cardiovasc Drug Rev, 2003, 21(3): 199-215.
  • 4BOLEGO C, POLI A, CIGNARELLA A, et al. Novel statins: pharmacological and clinical results[J]. Cardiovasc Drugs Ther, 2002, 16(3): 251-257.
  • 5KOJIMA J, FUJINO H, YOSIMURA M, et al. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection[J]. J Chromatogr B Biomed Sci Appl, 1999, 724(1): 173-180.
  • 6ANDO H, TSURUOKA S, YANAGIHARA H, et ol. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin[J]. Br J Clin Pharmacol, 2005, 60(5): 494-497.

同被引文献45

  • 1何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 2梁燕,石全,周燕文.氯诺昔康片在健康人体的药代动力学及生物等效性[J].中国临床药理学杂志,2006,22(5):336-339. 被引量:5
  • 3杭东元,许新芳.氯诺昔康联合芬太尼用于骨科术后静脉自控镇痛的临床观察[J].中国血液流变学杂志,2006,16(4):714-715. 被引量:2
  • 4罗汕,刘坚义,王伟雄,姚晓军,徐凡,冯骏,沈波.氯诺昔康联合黄体酮治疗急性肾绞痛疗效观察[J].广东医学,2007,28(5):814-815. 被引量:7
  • 5SAITO Y, YAMADA N, TERAMOTO T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia[J]. Atherosclerosis, 2002, 162(2): 373- 379.
  • 6KAJINAMI K, TAKEKOSHI N, SAITO Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reduetaae inhibitor[J].Cardiovasc Drug Rev, 2003, 21 (3) : 199-215.
  • 7BOLEGO C, POLl A, CIGNARELLA A, et al. Novel statins: pharmacological and clinical results[J]. Cardiovasc Drugs Ther, 2002, 16(3): 251-257.
  • 8FUJINO H, YAMADA M, SHIMADA S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization[J]. Xenobiotica, 2003, 33(1):27-41.
  • 9TIAN L, HUANG YL, JIA YH, et al. Development and validation of a liquid chromatography-tandem mass spectrometric assay for Pitavastatin and its lactone in human plasma and urine [J]. J Chromatogr B, 2008, 865: 127-132.
  • 10YAMADA I, FUJINO H, SHIMADA S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans[J]. Xenobiotica, 2003, 33(7): 789-803.

引证文献9

二级引证文献16

;
使用帮助 返回顶部